suma/edema

CROSS-REFERENCE TO RELATED APPLICATION This patent application is related to U.S. patent application, entitled "IMPROVED SENSITIVITY AND SPECIFICITY OF PULMONARY EDEMA DETECTION WHEN USING TRANSTHORACIC IMPEDANCE," filed even date herewith Ser. No. 11/126,723 which is hereby incorporated by

CROSS-REFERENCE TO RELATED APPLICATION This patent application is related to U.S. Pat. Application Ser. No. 11/126,689, entitled "ENHANCEMENTS TO THE DETECTION OF PULMONARY EDEMA WHEN USING TRANSTHORACIC IMPEDANCE," filed May 11, 2005, which is hereby incorporated by reference in its

TECHNICAL FIELD This patent document pertains generally to medical systems, devices, and methods, and more particularly, but not by way of limitation, to medical systems, devices, and methods for the detection of pulmonary edema using thoracic impedance. BACKGROUND Variations in how much fluid is

The present invention relates to furo[2, 3d]pyrimidine derivatives having the general formula (I) ##STR2## wherein R.sub.1 represents a lower alkyl, a lower alkenyl or an aralkyl group, and R.sub.2 represents a lower alkyl, unsubstituted phenyl, carboxyl, methylsulphonyl, methoxycarbonyl or a

CROSS-REFERENCES TO RELATED APPLICATIONS This application is a U.S. national phase application of International PCT Patent Application No. PCT/KR2011/006094, which was filed on Aug. 18, 2011, which claims priority to Korean Patent Application Nos. 10-2010-0123086, filed Dec. 3, 2010;

FIELD OF THE INVENTION This invention relates to an electronic stimulator, and more specifically to an electronic nerve and muscle stimulator and method useful for preventing venous thrombo embolism, venostasis, varicose veins, orthostatic hypotension, ankle edema, and leg discomfort resulting from

TECHNICAL FIELD This invention relates to a novel porcine derived physiologically active peptide (CNP) having natriuretic and hypotensive actions, as well as the capability of suppressing the growth of vascular smooth muscle cells. BACKGROUND ART Two kinds of peptide hormones, named "atrial

TECHNICAL FIELD The present invention relates to the field of immunology and more particularly relates to methods and compositions for treating, preventing or reducing anthrax infection in humans or animals. BACKGROUND OF THE INVENTION Anthrax is a disease caused by the sporulating bacteria Bacillus

FIELD OF THE INVENTION The present invention relates to methods and apparatuses for use in treating tissue swelling, including cerebral edema, compartment syndrome and congestive heart failure. In another aspect, the invention relates to diagnostic and therapeutic methods and apparatuses that

BACKGROUND OF THE INVENTION The plasma membranes of all cells are bilayered and carry a net negative charge at the inner layer and a net positive charge at the outer layer, which is affected by the flow of ions in and out of the cell. When the voltage potential (net difference in electric charge

TECHNICAL FIELD The present invention relates to a guanidine compound which is useful as an active ingredient of a pharmaceutical composition, in particular, a pharmaceutical composition for preventing and/or treating vascular adhesion protein-1 (hereinafter abbreviated as VAP-1)-related

TECHNICAL FIELD The present invention relates to a guanidine compound which is useful as an active ingredient of a pharmaceutical composition, in particular, a pharmaceutical composition for preventing and/or treating vascular adhesion protein-1 (hereinafter abbreviated as VAP-1)-related

TECHNICAL FIELD The present invention relates to a guanidine compound which is useful as an active ingredient of a pharmaceutical composition, in particular, a pharmaceutical composition for preventing and/or treating vascular adhesion protein-1 (hereinafter abbreviated as VAP-1)-related

FIELD OF THE INVENTION The invention relates to taking the five crystalline forms of compound, XLF-III-43, as crude drug, the preparation methods of the five crystalline forms of XLF-III-43, taking the sterling of the five crystalline forms and mixed crystals with different proportions as active

BRIEF SUMMARY OF THE INVENTION The present invention relates to imidazole derivatives of the formula ##STR3## wherein R.sup.1 and R.sup.2 each is lower alkyl, X is a residue of the formula ##STR4## R.sup.3 is hydrogen and R.sup.4 is hydrogen or lower alkyl or R.sup.3 and R.sup.4 taken together are